Your browser doesn't support javascript.
loading
Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network Registry.
Patel, Siddharth M; Berg, David D; Bohula, Erin A; Baird-Zars, Vivian M; Barsness, Gregory W; Chaudhry, Sunit-Preet; Chonde, Meshe D; Cooper, Howard A; Ginder, Curtis; Jentzer, Jacob C; Kontos, Michael C; Miller, P Elliott; Newby, L Kristin; O'Brien, Connor G; Park, Jeong-Gun; Pierce, Matthew J; Pisani, Barbara A; Potter, Brian J; Shah, Kevin S; Teuteberg, Jeffrey J; Katz, Jason N; van Diepen, Sean; Morrow, David A.
Afiliação
  • Patel SM; Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.M.P., D.D.B., E.A.B., V.M.B.-Z., C.G., J.-G.P., D.A.M.).
  • Berg DD; Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.M.P., D.D.B., E.A.B., V.M.B.-Z., C.G., J.-G.P., D.A.M.).
  • Bohula EA; Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.M.P., D.D.B., E.A.B., V.M.B.-Z., C.G., J.-G.P., D.A.M.).
  • Baird-Zars VM; Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.M.P., D.D.B., E.A.B., V.M.B.-Z., C.G., J.-G.P., D.A.M.).
  • Barsness GW; Department of Cardiovascular Medicine, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN (G.W.B., J.C.J.).
  • Chaudhry SP; Department of Cardiology, St Vincent Heart Center, Indianapolis, IN (S.-P.C.).
  • Chonde MD; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA (M.D.C.).
  • Cooper HA; Department of Cardiology, Westchester Medical Center, Valhalla, NY (H.A.C.).
  • Ginder C; Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.M.P., D.D.B., E.A.B., V.M.B.-Z., C.G., J.-G.P., D.A.M.).
  • Jentzer JC; Department of Cardiovascular Medicine, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN (G.W.B., J.C.J.).
  • Kontos MC; Division of Cardiology, Department of Medicine, Virginia Commonwealth University, Richmond (M.C.K.).
  • Miller PE; Section of Cardiovascular Medicine, Yale University, New Haven, CT (P.E.M.).
  • Newby LK; Division of Cardiology and Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (L.K.N.).
  • O'Brien CG; Division of Cardiology, Department of Medicine, University of California San Francisco (C.G.O.B.).
  • Park JG; Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.M.P., D.D.B., E.A.B., V.M.B.-Z., C.G., J.-G.P., D.A.M.).
  • Pierce MJ; Department of Cardiology, Northwell Health, Zucker School of Medicine, New Hyde Park, NY (M.J.P.).
  • Pisani BA; Section of Cardiovascular Medicine, Department of Internal Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC (B.A.P.).
  • Potter BJ; Cardiology Service, Department of Medicine, Centre Hospitalier de l'Université de Montréal Research Center and Cardiovascular Center, Quebec, QC, Canada (B.J.P.).
  • Shah KS; Division of Cardiology, Department of Medicine, University of Utah, Salt Lake City (K.S.S.).
  • Teuteberg JJ; Division of Cardiovascular Medicine, Stanford University School of Medicine, CA (J.J.T.).
  • Katz JN; Division of Cardiovascular Medicine, Department of Medicine, New York University School of Medicine, New York (J.N.K.).
  • van Diepen S; Department of Critical Care Medicine and Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, AB, Canada (S.v.D.).
  • Morrow DA; Levine Cardiac Intensive Care Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.M.P., D.D.B., E.A.B., V.M.B.-Z., C.G., J.-G.P., D.A.M.).
Circ Heart Fail ; 17(5): e011736, 2024 May.
Article em En | MEDLINE | ID: mdl-38587438
ABSTRACT

BACKGROUND:

Associations of early changes in vasoactive support with cardiogenic shock (CS) mortality remain incompletely defined.

METHODS:

The Critical Care Cardiology Trials Network is a multicenter registry of cardiac intensive care units. Patients admitted with CS (2018-2023) had vasoactive dosing assessed at 4 and 24 hours from cardiac intensive care unit admission and quantified by the vasoactive-inotropic score (VIS). Prognostic associations of VIS at both time points, as well as change in VIS from 4 to 24 hours, were examined. Interaction testing was performed based on mechanical circulatory support status.

RESULTS:

Among 3665 patients, 82% had a change in VIS <10, with 7% and 11% having a ≥10-point increase and decrease from 4 to 24 hours, respectively. The 4 and 24-hour VIS were each associated with cardiac intensive care unit mortality (13%-45% and 11%-73% for VIS <10 to ≥40, respectively; Ptrend <0.0001 for each). Stratifying by the 4-hour VIS, changes in VIS from 4 to 24 hours had a graded association with mortality, ranging from a 2- to >4-fold difference in mortality comparing those with a ≥10-point increase to ≥10-point decrease in VIS (Ptrend <0.0001). The change in VIS alone provided good discrimination of cardiac intensive care unit mortality (C-statistic, 0.72 [95% CI, 0.70-0.75]) and improved discrimination of the 24-hour Sequential Organ Failure Assessment score (0.72 [95% CI, 0.69-0.74] to 0.76 [95% CI, 0.74-0.78]) and the clinician-assessed Society for Cardiovascular Angiography and Interventions shock stage (0.72 [95% CI, 0.70-0.74] to 0.77 [95% CI, 0.75-0.79]). Although present in both groups, the mortality risk associated with VIS was attenuated in patients managed with versus without mechanical circulatory support (odds ratio per 10-point higher 24-hour VIS, 1.36 [95% CI, 1.23-1.49] versus 1.84 [95% CI, 1.69-2.01]; Pinteraction <0.0001).

CONCLUSIONS:

Early changes in the magnitude of vasoactive support in CS are associated with a gradient of risk for mortality. These data suggest that early VIS trajectory may improve CS prognostication, with the potential to be leveraged for clinical decision-making and research applications in CS.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Choque Cardiogênico / Sistema de Registros Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Choque Cardiogênico / Sistema de Registros Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article